Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis
patients.
Author(s): Mohammadpour AH(1), Falsoleiman H, Shamsara J, Allah Abadi G, Rasooli R, Ramezani
M.
Affiliation(s): Author information:
(1)Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical
Sciences, Mashhad, Iran. ramezanim@mums.ac.ir.
Publication date & source: 2014, Iran Biomed J. , 18(1):23-7
BACKGROUND: Inflammation is involved in development, progression, and
complications of atherosclerotic disease. Clinical studies have indicated that
the level of monocyte chemoattractant protein 1 (MCP-1), IL-18, and adhesion
molecules correlates with the severity of atherosclerosis and can predict future
cardiovascular events. Experimental studies have shown pentoxifylline (PTX)
reduces these factors in animal models. The purpose of the present pilot study
was to evaluate effect of PTX on a group of inflammatory biomarkers in patients
with coronary artery disease (CAD).
METHODS: Forty patients with angiographically documented CAD, who fulfilled
inclusion and exclusion criteria, were entered in the double-blind, randomized,
pilot clinical study. The patients were randomly given PTX (400 mg three times
daily) or placebo (3 tab/day) for 2 months. Serum concentrations of MCP-1, IL-18,
intercellular adhesion Molecule 1 (ICAM-1), and vascular cell adhesion molecule 1
(VCAM-1) were measured before and at the end of intervention by enzyme-linked
immunosorbant assay.
RESULTS: Our study showed that the serum levels of ICAM-1 and VCAM-1 was
decreased in the study population after two-month treatment (P<0.05).
CONCLUSION: Based on the results of our pilot study, administration of PTX in CAD
patients significantly decreases adhesion molecules levels.
|